These and other mechanisms, including MHC class I re-expression in neuroblastoma cells stably transfected to express NTRK1 and upregulation of immune modulating genes by NTRK1, corroborate the idea that excellent prognosis in patients with NTRK1-expressing neuroblastomas could be attributed at least in part through pro-immunogenic features mediated by NTRK1 (21). This evidence concerns the gene NTRK1 and neuroblastoma.